Gilead CEO, CFO, and Two Others Sell 21,000 Shares Under 10b5-1 Plan

Gilead Sciences (NASDAQ: GILD) executives including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO) sold a total of 21,000 shares of common stock on June 15 and July 1 under prearranged Rule 10b5-1 trading plans.[1][2][3] All three transactions were disclosed as planned trades, and even after the sales, each executive retains a shareholding in the hundreds of thousands of shares, limiting insider dilution.[1][2][3]

Transaction Overview

Executive	Title	Trade Date	Shares Sold	Average Price (USD)	Total Proceeds (USD)	Transaction Type
Andrew D. Dickinson	Chief Financial Officer (CFO)	2026-06-15	3,000	125.40	376,200	Open-market Sale[1]
Johanna Mercier	Chief Comm & Corp Aff Officer	2026-06-15	3,000	approx. 123.72 (3-trade average)	approx. 371,763.08	Open-market Sale[2]
Daniel Patrick O'Day	Chairman and Chief Executive Officer (CEO)	2026-07-01	15,000	approx. 126.37 (2-trade average)	approx. 1,884,435.93	Open-market Sale[3]

The average price and total amounts are simple calculations based on disclosed individual trade prices and quantities; all other figures are directly sourced from the filings.[1][2][3]

Detailed Transactions by Executive

CFO Andrew D. Dickinson

• On June 15, 2026, he sold 3,000 shares of common stock at $125.40 per share, securing $376,200 in total proceeds.[1]
• This transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.[1]
• After the trade, Dickinson directly holds 171,646 shares, which at the sale price equates to approximately $2,152,668.40.[1]

Chief Comm & Corp Aff Officer Johanna Mercier

• On June 15, 2026, she sold a total of 3,000 shares in three separate open-market transactions.[2]
  • 1,480 shares at $123.4166 per share, totaling $182,657.57.[2]
  • 1,070 shares at $123.9958 per share, totaling $132,675.51.[2]
  • 450 shares at $125.40 per share, totaling $56,430.[2]
• All three trades were made under a Rule 10b5-1 trading plan adopted on February 20, 2025, resulting in total proceeds of approximately $371,000.[2]
• After the sales, Mercier continues to hold approximately 124,234 shares of Gilead common stock.[2]

Chairman and CEO Daniel Patrick O'Day

• On July 1, 2026, he sold a total of 15,000 shares in two separate open-market transactions.[3]
  • 11,900 shares at $126.0897 per share, generating $1,490,503.43 in proceeds.[3]
  • 3,100 shares at $127.075 per share, generating $393,932.50 in proceeds.[3]
• According to the filings, the actual execution prices for the two trades ranged between $125.59 and $127.44.[3]
• The sales were made under a Rule 10b5-1 trading plan adopted on February 25, 2026, and after the transactions, O'Day continues to hold 607,133 shares.[3]

Post-Transaction Shareholdings Comparison

Executive	Shares Held After Sale	Notes
Andrew D. Dickinson	171,646 shares	approx. $2.15 million at the sale price[1]
Johanna Mercier	124,234 shares	Maintains a shareholding in the hundreds of thousands[2]
Daniel P. O'Day	607,133 shares	Executive with the largest shareholding[3]

All three Form 4 filings were made under pre-established Rule 10b5-1 plans, suggesting that these trades are planned liquidity events rather than opportunistic timing decisions, so shareholders should focus on the share structure and remaining holdings rather than interpreting them as short-term insider sell signals.[1][2][3]